Roth MKM Reiterates Buy on Immix Biopharma, Maintains $14 Price Target
Portfolio Pulse from richadhand@benzinga.com
Roth MKM analyst Jonathan Aschoff has reiterated a 'Buy' rating on Immix Biopharma (NASDAQ:IMMX) and maintained a $14 price target.
August 14, 2023 | 2:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immix Biopharma's stock may see positive movement as Roth MKM analyst maintains a 'Buy' rating and a $14 price target.
Analyst ratings often influence the market's perception of a stock. In this case, the 'Buy' rating from Roth MKM, a reputable financial firm, coupled with a maintained price target of $14, suggests a positive outlook for Immix Biopharma. This could lead to increased investor interest and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100